Health
Moderna and Merck say personalized mRNA vaccine cut melanoma risk by 42% in trial
In a large trial tied to the ESMO Congress in Madrid, an individualized mRNA vaccine given with standard immunotherapy lowered a key melanoma risk measure by 42% compared with immunotherapy alone, according to company data relayed by STAT, Ars Technica and Reuters.